Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.33
(-4.68%)
SEK 1.33
(-4.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.89 Million SEK | 4.98% |
| 2022 | 20.85 Million SEK | 19.87% |
| 2021 | 17.4 Million SEK | 60.89% |
| 2020 | 10.81 Million SEK | -12.07% |
| 2019 | 12.3 Million SEK | 140.28% |
| 2018 | 5.11 Million SEK | 185358.92% |
| 2017 | 2760.18 SEK | -99.97% |
| 2016 | 10.06 Million SEK | 771.16% |
| 2015 | 1.15 Million SEK | 4005.14% |
| 2014 | 28.13 Thousand SEK | 277.22% |
| 2013 | 7459.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.83 Million SEK | 16.65% |
| 2024 Q1 | 4.14 Million SEK | -10.9% |
| 2023 Q2 | 7.15 Million SEK | 43.76% |
| 2023 Q4 | 4.65 Million SEK | -8.93% |
| 2023 FY | 21.89 Million SEK | 4.98% |
| 2023 Q1 | 4.98 Million SEK | -11.76% |
| 2023 Q3 | 5.1 Million SEK | -28.68% |
| 2022 Q2 | 5.81 Million SEK | 30.17% |
| 2022 FY | 20.85 Million SEK | 19.87% |
| 2022 Q4 | 5.64 Million SEK | 14.51% |
| 2022 Q3 | 4.92 Million SEK | -15.25% |
| 2022 Q1 | 4.46 Million SEK | -21.83% |
| 2021 FY | 17.4 Million SEK | 60.89% |
| 2021 Q1 | 2.64 Million SEK | 6.47% |
| 2021 Q2 | 3.78 Million SEK | 42.75% |
| 2021 Q3 | 5.25 Million SEK | 39.05% |
| 2021 Q4 | 5.71 Million SEK | 8.75% |
| 2020 Q2 | 2.41 Million SEK | -25.08% |
| 2020 FY | 10.81 Million SEK | -12.07% |
| 2020 Q3 | 2.69 Million SEK | 11.52% |
| 2020 Q1 | 3.22 Million SEK | -16.42% |
| 2020 Q4 | 2.48 Million SEK | -7.62% |
| 2019 FY | 12.3 Million SEK | 140.28% |
| 2019 Q2 | 2.66 Million SEK | -5.4% |
| 2019 Q4 | 3.85 Million SEK | 21.46% |
| 2019 Q1 | 2.81 Million SEK | 130.41% |
| 2019 Q3 | 3.17 Million SEK | 19.23% |
| 2018 Q3 | 858.01 Thousand SEK | -44.69% |
| 2018 FY | 5.11 Million SEK | 185358.92% |
| 2018 Q4 | 1.22 Million SEK | 42.34% |
| 2018 Q2 | 1.55 Million SEK | 4.21% |
| 2018 Q1 | 1.48 Million SEK | 0.0% |
| 2017 Q1 | 2.45 Million SEK | 9.85% |
| 2017 FY | 2760.18 SEK | -99.97% |
| 2017 Q3 | 2.86 Million SEK | -6.7% |
| 2017 Q2 | 3.07 Million SEK | 25.39% |
| 2016 Q1 | 256.96 Thousand SEK | -28.5% |
| 2016 FY | 10.06 Million SEK | 771.16% |
| 2016 Q4 | 2.23 Million SEK | 116.53% |
| 2016 Q2 | 442.16 Thousand SEK | 72.07% |
| 2016 Q3 | 1.03 Million SEK | 133.06% |
| 2015 Q4 | 359.36 Thousand SEK | 11.75% |
| 2015 Q3 | 321.57 Thousand SEK | 0.0% |
| 2015 FY | 1.15 Million SEK | 4005.14% |
| 2014 FY | 28.13 Thousand SEK | 277.22% |
| 2013 FY | 7459.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.554% |
| AcouSort AB (publ) | 25.87 Million SEK | 15.385% |
| Active Biotech AB (publ) | 44.8 Million SEK | 51.137% |
| Alzinova AB (publ) | 36.39 Million SEK | 39.842% |
| Amniotics AB (publ) | 29.07 Million SEK | 24.687% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -49.423% |
| BioArctic AB (publ) | 89.62 Million SEK | 75.571% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.934% |
| Cantargia AB (publ) | 290.01 Million SEK | 92.45% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 22.704% |
| Genovis AB (publ.) | 88.19 Million SEK | 75.175% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 80.973% |
| Mendus AB (publ) | 129.13 Million SEK | 83.045% |
| Kancera AB (publ) | 63.07 Million SEK | 65.288% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -296.72% |
| LIDDS AB (publ) | 27.75 Million SEK | 21.105% |
| Lipum AB (publ) | 37.3 Million SEK | 41.311% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -201.833% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 83.89% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -33.498% |
| NextCell Pharma AB | -576.01 Thousand SEK | 3901.09% |
| OncoZenge AB (publ) | 15.9 Million SEK | -37.661% |
| Saniona AB (publ) | 1.07 Million SEK | -1932.962% |
| Simris Alg AB (publ) | 38.64 Million SEK | 43.339% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 93.19% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 93.878% |
| Xintela AB (publ) | 57.31 Million SEK | 61.799% |
| Ziccum AB (publ) | 27.87 Million SEK | 21.461% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -201.252% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 87.952% |
| CombiGene AB (publ) | 44.14 Million SEK | 50.401% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 84.687% |
| Intervacc AB (publ) | 79.78 Million SEK | 72.557% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 92.87% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 48.642% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -23.819% |
| Corline Biomedical AB | 30.16 Million SEK | 27.423% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 62.27% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 73.674% |
| Aptahem AB (publ) | 10.01 Million SEK | -118.667% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 83.745% |
| Fluicell AB (publ) | 28.61 Million SEK | 23.49% |
| Biovica International AB (publ) | 133.72 Million SEK | 83.626% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -10.637% |
| Abliva AB (publ) | 27.86 Million SEK | 21.428% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 88.685% |
| 2cureX AB (publ) | 36.51 Million SEK | 40.043% |
| I-Tech AB | 40.14 Million SEK | 45.464% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 97.452% |
| Cyxone AB (publ) | 28.21 Million SEK | 22.397% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 79.98% |
| Biosergen AB | 26.8 Million SEK | 18.33% |
| Nanologica AB (publ) | 69.88 Million SEK | 68.671% |
| SynAct Pharma AB | 224.49 Million SEK | 90.247% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 50.437% |
| BioInvent International AB (publ) | 441.4 Million SEK | 95.04% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 8.597% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 92.443% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -178.695% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 80.259% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -48.946% |